{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T09:32:32Z","timestamp":1682674352476},"reference-count":49,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2013.0126","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T09:25:18Z","timestamp":1525253118000},"source":"Crossref","is-referenced-by-count":4,"title":["The Conservative and Interventional Treatment of the Complications of Liver Cirrhosis"],"prefix":"10.3238","author":[{"given":"Tilman","family":"Sauerbruch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Appenrodt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Spengler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2013,2,22]]},"reference":[{"key":"10.3238\/arztebl.2013.0126_ref1","doi-asserted-by":"crossref","unstructured":"Schepke M, Kleber G, N\u00fcrnberg D, et al.: German Study Group for the Primary Prophylaxis of Variceal Bleeding. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2004; 40: 65\u201372.","DOI":"10.1002\/hep.20284"},{"key":"10.3238\/arztebl.2013.0126_ref2","doi-asserted-by":"crossref","unstructured":"de Franchis R, Baveno V Faculty: Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Heptol 2010; 53: 762\u20138.","DOI":"10.1016\/j.jhep.2010.06.004"},{"key":"10.3238\/arztebl.2013.0126_ref3","doi-asserted-by":"crossref","unstructured":"Merkel C, Marin R, Angeli P, et al.: Gruppo Triveneto per l\u2019ipertensione Portale. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 2004; 127: 476\u201384.","DOI":"10.1053\/j.gastro.2004.05.004"},{"key":"10.3238\/arztebl.2013.0126_ref4","doi-asserted-by":"crossref","unstructured":"D\u2019Amico G, Criscuoli V, Fili D, Mocciaro F, Pagliaro L: Meta-analysis of trials for variceal bleeding. Hepatology 2002; 36(4 Pt 1): 1023\u20134; author\u00b4s reply 1024\u20135.","DOI":"10.1053\/jhep.2002.34737"},{"key":"10.3238\/arztebl.2013.0126_ref5","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Pag\u00e1n JC, Caca K, Bureau C, et al.: Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010; 362: 2370\u20139.","DOI":"10.1056\/NEJMoa0910102"},{"key":"10.3238\/arztebl.2013.0126_ref6","doi-asserted-by":"crossref","unstructured":"Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, et al.: Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding \u2013 an updated Cochrane review. Aliment Pharmacol Ther 2011; 34: 509\u2013518.","DOI":"10.1111\/j.1365-2036.2011.04746.x"},{"key":"10.3238\/arztebl.2013.0126_ref7","unstructured":"Funakoshi N, S\u00e9galas-Largey F, Duny Y, et al.: Benefit of combination \u00df-blocker and endoscopic treatment to prevent variceal rebleeding: a meta-analysis. World J Gastroenterol 2010; 16: 5982\u201392."},{"key":"10.3238\/arztebl.2013.0126_ref8","doi-asserted-by":"crossref","unstructured":"Ding SH, Liu J, Wang JP: Efficacy of beta-adrenergic blocker plus 5-isosorbide mononitrate and endoscopic band ligation for prophylaxis of esophageal variceal rebleeding: a meta-analysis. World J Gastroenterol 2009; 15: 2151\u20135.","DOI":"10.3748\/wjg.15.2151"},{"key":"10.3238\/arztebl.2013.0126_ref9","doi-asserted-by":"crossref","unstructured":"Zheng M, Chen Y, Bai J, et al.: Transjugular intrahepatic portosystemic shunt versus endoscopic therapy in the secondary prophylaxis of variceal rebleeding in cirrhotic patients: meta-analysis update. J Clin Gastroenterol 2008; 42: 507\u201316.","DOI":"10.1097\/MCG.0b013e31815576e6"},{"key":"10.3238\/arztebl.2013.0126_ref10","doi-asserted-by":"crossref","unstructured":"Gerbes AL, G\u00fclberg V, Sauerbruch T, et al.: German S 3-guideline \u201cascites, spontaneous bacterial peritonitis, hepatorenal syndrome\u201d. Z Gastroenterol 2011; 49: 749\u201379.","DOI":"10.1055\/s-0031-1273405"},{"key":"10.3238\/arztebl.2013.0126_ref11","doi-asserted-by":"crossref","unstructured":"R\u00f6ssle M, Ochs A, G\u00fclberg V, et al.: A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342: 1701\u20137.","DOI":"10.1056\/NEJM200006083422303"},{"key":"10.3238\/arztebl.2013.0126_ref12","doi-asserted-by":"crossref","unstructured":"Salerno F, Merli M, Riggio O, et al.: Cazzaniga M, Valeriano V, Pozzi M, Nicolini A, Salvatori F. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004; 40: 629\u201335.","DOI":"10.1002\/hep.20364"},{"key":"10.3238\/arztebl.2013.0126_ref13","doi-asserted-by":"crossref","unstructured":"Salerno F, Camm\u00e0 C, Enea M, R\u00f6ssle M, Wong F: Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007; 133: 825\u201334.","DOI":"10.1053\/j.gastro.2007.06.020"},{"key":"10.3238\/arztebl.2013.0126_ref14","doi-asserted-by":"crossref","unstructured":"Gluud LL, Christensen K, Christensen E, Krag A: Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010; 51: 576\u201384.","DOI":"10.1002\/hep.23286"},{"key":"10.3238\/arztebl.2013.0126_ref15","doi-asserted-by":"crossref","unstructured":"Gin\u00e8s P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D: HypoCAT Study Investigators. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 2008; 48: 204\u201313.","DOI":"10.1002\/hep.22293"},{"key":"10.3238\/arztebl.2013.0126_ref16","doi-asserted-by":"crossref","unstructured":"Bruix J, Sherman M: Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020\u20132.","DOI":"10.1002\/hep.24199"},{"key":"10.3238\/arztebl.2013.0126_ref17","doi-asserted-by":"crossref","unstructured":"European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2012; 56: 908\u201343.","DOI":"10.1016\/j.jhep.2011.12.001"},{"key":"10.3238\/arztebl.2013.0126_ref18","doi-asserted-by":"crossref","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al.: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378\u201390.","DOI":"10.1056\/NEJMoa0708857"},{"key":"10.3238\/arztebl.2013.0126_ref19","doi-asserted-by":"crossref","unstructured":"Cholongitas E, Marelli L, Shusang V, et al.: A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transpl 2006; 12: 1049\u201361.","DOI":"10.1002\/lt.20824"},{"key":"10.3238\/arztebl.2013.0126_ref20","doi-asserted-by":"crossref","unstructured":"H\u00e4ussinger D, Schliess F: Pathogenetic mechanisms of hepatic encephalopathy. Gut 2008; 57: 1156\u201365.","DOI":"10.1136\/gut.2007.122176"},{"key":"10.3238\/arztebl.2013.0126_ref21","doi-asserted-by":"crossref","unstructured":"Zhan T, Stremmel W: The diagnosis and treatment of minimal hepatic encephalopathy. Dtsch Arztebl Int 2012; 109(10): 180\u20137.","DOI":"10.3238\/arztebl.2012.0180"},{"key":"10.3238\/arztebl.2013.0126_ref22","doi-asserted-by":"crossref","unstructured":"Als-Nielsen B, Gluud LL, Gluud C: Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004; 328: 1046.","DOI":"10.1136\/bmj.38048.506134.EE"},{"key":"10.3238\/arztebl.2013.0126_ref23","doi-asserted-by":"crossref","unstructured":"Sharma BC, Sharma P, Agrawal A, Sarin SK: Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009; 137: 885\u201391.","DOI":"10.1053\/j.gastro.2009.05.056"},{"key":"10.3238\/arztebl.2013.0126_ref24","doi-asserted-by":"crossref","unstructured":"Bass NM, Mullen KD, Sanyal A, et al.: Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071\u201381.","DOI":"10.1056\/NEJMoa0907893"},{"key":"10.3238\/arztebl.2013.0126_ref25","doi-asserted-by":"crossref","unstructured":"McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC: Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev. 2011; 11: CD008716.","DOI":"10.1002\/14651858.CD008716.pub2"},{"key":"10.3238\/arztebl.2013.0126_ref26","doi-asserted-by":"crossref","unstructured":"Sauerbruch T, Wotzka R, K\u00f6pcke W, et al.: Prophylactic sclerotherapy before the first episode of variceal hemorrhage in patients with cirrhosis. N Engl J Med 1988; 319: 8\u201315.","DOI":"10.1056\/NEJM198807073190102"},{"key":"10.3238\/arztebl.2013.0126_ref27","unstructured":"Niederau C: Epidemiologie der Leberzirrhose. Hepatitis & More 2011; 1: 11\u201314."},{"key":"10.3238\/arztebl.2013.0126_ref28","doi-asserted-by":"crossref","unstructured":"Hearnshaw SA, Logan RF, Lowe D, Travis SP, Murphy MF, Palmer KR: Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011; 60: 1327\u201335.","DOI":"10.1136\/gut.2010.228437"},{"key":"10.3238\/arztebl.2013.0126_ref29","doi-asserted-by":"crossref","unstructured":"Mishra SR, Sharma BC, Kumar A, Sarin SK: Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: a randomized controlled trial. J Hepatol 2011; 54: 1161\u20137.","DOI":"10.1016\/j.jhep.2010.09.031"},{"key":"10.3238\/arztebl.2013.0126_ref30","doi-asserted-by":"crossref","unstructured":"Augustin S, Altamirano J, Gonz\u00e1lez A, et al.: Effectiveness of combined pharmacologic and ligation therapy in high-risk patients with acute esophageal variceal bleeding. Am J Gastroenterol 2011; 106: 1787\u201395.","DOI":"10.1038\/ajg.2011.173"},{"key":"10.3238\/arztebl.2013.0126_ref31","doi-asserted-by":"crossref","unstructured":"Arvaniti V, D\u2019Amico G, Fede G, et al.: Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139: 1246\u201356, 1256.e1\u20135.","DOI":"10.1053\/j.gastro.2010.06.019"},{"key":"10.3238\/arztebl.2013.0126_ref32","doi-asserted-by":"crossref","unstructured":"Angermayr B, Cejna M, Koenig F, et al.: Vienna TIPS Study Group. Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. Hepatology 2003; 38: 1043\u201350.","DOI":"10.1002\/hep.1840380431"},{"key":"10.3238\/arztebl.2013.0126_ref33","doi-asserted-by":"crossref","unstructured":"Gines P, Quintero E, Arroyo V, et al.: Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7: 122\u20138.","DOI":"10.1002\/hep.1840070124"},{"key":"10.3238\/arztebl.2013.0126_ref34","doi-asserted-by":"crossref","unstructured":"Sola-Vera J, Mi\u00f1ana J, Ricart E: Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003; 37: 1147\u201353.","DOI":"10.1053\/jhep.2003.50169"},{"key":"10.3238\/arztebl.2013.0126_ref35","unstructured":"Salerno F, Gerbes A, Gin\u00e8s P, Wong F, Arroyo V: Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310\u20138."},{"key":"10.3238\/arztebl.2013.0126_ref36","doi-asserted-by":"crossref","unstructured":"Gerbes AL, Huber E, G\u00fclberg V: Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration. Gastroenterology 2009; 137: 1179; author reply 1179\u201381.","DOI":"10.1053\/j.gastro.2009.03.064"},{"key":"10.3238\/arztebl.2013.0126_ref37","doi-asserted-by":"crossref","unstructured":"Brensing KA, Textor J, Perz J, et al.: Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47: 288\u201395.","DOI":"10.1136\/gut.47.2.288"},{"key":"10.3238\/arztebl.2013.0126_ref38","doi-asserted-by":"crossref","unstructured":"Forner A, Llovet JM, Bruix J: Hepatocellular carcinoma. Lancet 2012; 379: 1245\u201355.","DOI":"10.1016\/S0140-6736(11)61347-0"},{"key":"10.3238\/arztebl.2013.0126_ref39","doi-asserted-by":"crossref","unstructured":"Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208\u201336.","DOI":"10.1002\/hep.20933"},{"key":"10.3238\/arztebl.2013.0126_ref40","doi-asserted-by":"crossref","unstructured":"Llovet JM, Schwartz M, Mazzaferro V: Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25: 181\u2013200.","DOI":"10.1055\/s-2005-871198"},{"key":"10.3238\/arztebl.2013.0126_ref41","doi-asserted-by":"crossref","unstructured":"Sangro B, Carpanese L, Cianni R, et al.: European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY). Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011; 54: 868\u201378. doi: 10.1002\/hep.24451.","DOI":"10.1002\/hep.24451"},{"key":"10.3238\/arztebl.2013.0126_ref42","doi-asserted-by":"crossref","unstructured":"Butterworth RF: Hepatic encephalopathy: a central neuroinflammatory disorder? Hepatology 2011; 53: 1372\u20136.","DOI":"10.1002\/hep.24228"},{"key":"10.3238\/arztebl.2013.0126_ref43","doi-asserted-by":"crossref","unstructured":"Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT: Hepatic encephalopathy\u2013definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716\u201321.","DOI":"10.1053\/jhep.2002.31250"},{"key":"10.3238\/arztebl.2013.0126_ref44","doi-asserted-by":"crossref","unstructured":"Bajaj JS: Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther 2010; 31: 537\u201347.","DOI":"10.1111\/j.1365-2036.2009.04211.x"},{"key":"10.3238\/arztebl.2013.0126_ref45","doi-asserted-by":"crossref","unstructured":"Prakash R, Mullen KD: Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 2010; 7: 515\u201325.","DOI":"10.1038\/nrgastro.2010.116"},{"key":"10.3238\/arztebl.2013.0126_ref46","doi-asserted-by":"crossref","unstructured":"Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK: Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 2011; 106: 307\u201316.","DOI":"10.1038\/ajg.2010.455"},{"key":"10.3238\/arztebl.2013.0126_ref47","doi-asserted-by":"crossref","unstructured":"Bajaj JS, Heuman DM, Wade JB, et al.: Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011; 140: 478\u2013487.","DOI":"10.1053\/j.gastro.2010.08.061"},{"key":"10.3238\/arztebl.2013.0126_ref48","doi-asserted-by":"crossref","unstructured":"Neff GW, Jones M, Broda T, et al.: Durability of rifaximin response in hepatic encephalopathy. J Clin Gastroenterol 2012; 46: 168\u201371.","DOI":"10.1097\/MCG.0b013e318231faae"},{"key":"10.3238\/arztebl.2013.0126_ref49","doi-asserted-by":"crossref","unstructured":"Caldwell C, Werdiger N, Jakab S, et al.: Use of model for end-stage liver disease exception points for early liver transplantation and successful reversal of hepatic myelopathy with a review of the literature. Liver Transpl 2010; 16: 818 \u201326.","DOI":"10.1002\/lt.22077"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2013.0126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T13:29:01Z","timestamp":1638797341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2013.0126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,22]]},"references-count":49,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2013.0126","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,22]]}}}